Open Nav

Organized by Shanghai Newsummit Biopharma

Wednesday, November 13, 2013, 9:00 a.m. - 10:55 a.m., Room 403

9:00 a.m. - 9:40 a.m. China Healthcare Overview
• Chairman: Shao Ke, Chief Market Officer, Shanghai NewSummit Biopharma Group
The Development Trend and Requirements of Healthcare Service Industry in China
• Li Qing, Director, Development Center for Medical Science and Technology, Ministry of Health
An Overview of China Antibody Development Progress
• Guo Yajun, Director, National Engineering Center for Antibody Drug Research
9:40 a.m. - 10:20 a.m. Clinical Research and Market Development in China
This panel will explore the current state of international multi-center clinical trials in China as well as policy support for drugs originally developed in China. Specifically, this conversation will reference translational and evidence-based medicine supported by the “national project” and its use of third-party evaluations. Panelists will delve into the issue of post-market evaluations and their role in improving the standardization of clinical medicine. Determining international standards in China for multi-center clinical trials and how to accelerate the process of overseas R&D efforts will serve as core themes throughout the discussion.

  • Chen Biao, Director of National Center for Clinical Trials on Neurodegenerative Diseases, Xuanwu Hospital of Capital Medical University 
  • Irenee Robi, General Manager, Dynasty Biotech Co Ltd
  • Wang Xin, Chairman, Beijing Bionovo
  • Zeng Ling, General Manager, Quintiles China
  • Kelvin Shao, Chief Marketing Officer, Shanghai NewSummit Biopharma Group
10:20 a.m. - 10:55 a.m. Current Situation of Pharmacology and Toxicology Research in China and the Trend of Internationalization
Panelists will discuss the current state of pharmacology and toxicology research in China, including the influence of internationalization. Specific themes will include: GLP regulation between CFDA and FDA, meeting the CFDA requirements, the future of development of GLP research in China, the current situation of GLP research in China, the latest progress in overseas PK, PD, and drug safety research.

  • Huang Yangbin, Chief Technology Officer, Shanghai NewSummit Biopharma Group
  • Zuo Conglin, General Manager, Joinn Laboratories (Beijing)
  • Zheng Weiyi, General Manager, Nanjing Kangke Nuode Pharmaceutical Technology Co., Ltd
  • Wang Aipin, General Manager and Director of Drug Safety Evaluation Center, Peking Union Medical College, Chinese Academy of Medical Sciences
  • Chen Chunlin, Chairman, Shanghai Medicilon Inc